Mastocytosis

Current Problems in Dermatology

Volumn 10, Issue 5, 1998, Pages 177-210

  Tharp, Michael D ^{a,b,c,d,e,f,g}  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c PARKLAND HEALTH AND HOSPITAL SYSTEM   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e SOUTHWESTERN UNIVERSITY   (United States)

^f UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^g RUSH MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN; ALPHA2B INTERFERON; ANTIHISTAMINIC AGENT; ANTINEOPLASTIC AGENT; AZELASTINE; BETAMETHASONE DIPROPIONATE; CETIRIZINE; CHLORPHENIRAMINE; CIMETIDINE; CORTICOSTEROID; CROMOGLYCATE DISODIUM; DIPHENHYDRAMINE; DOXEPIN; FEXOFENADINE; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; LORATADINE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; PROSTAGLANDIN INHIBITOR; PSORALEN DERIVATIVE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; BONE DISEASE; CHILD; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE CLASSIFICATION; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; EOSINOPHILIA; GASTROINTESTINAL DISEASE; HUMAN; INTRALESIONAL DRUG ADMINISTRATION; LIVER DISEASE; LYMPHADENOPATHY; MAST CELL; MAST CELL LEUKEMIA; MASTOCYTOSIS; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; ORAL DRUG ADMINISTRATION; PROGNOSIS; PUVA; REVIEW; SKIN MANIFESTATION; SPLEEN DISEASE; SPLENECTOMY; TOPICAL DRUG ADMINISTRATION;

EID: 0031789002     PISSN: 10400486     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1040-0486(98)90006-0     Document Type: Review

References (224)

1. Nettleship E, Tay W. Rare forms of urticaria. Br Med J 1869; 2:323-4.
2. Ehrlich P. Bertage zur Kenntnis der Anilinfarbungen und ihrer Verwendurg in der Mikroskopischen Technik. Arch Mikros Anat 1877;13:263-77.
3. Sangster A. An anomalous mottled rash, accompanied by pruritus, factitious urticaria and pigmentation. Urticaria Pigmentosa? Trans Clin Svc, London 1878;11:161-3.
4. Unna PG, Beitrage W. Anatomie und Pathogenese dur urticaria simples und pigmentosa. Monatsschr Prakt Dermat 1887;3H:1.1
5. Touraine A, Solente G, Renault P. Urticaire pigmentaire avec reaction splenique et myelemique. Bull Soc Franc Dermat Et Syph 1933;40:1691.
6. Ellis JM. Urticaria pigmentosa: report of a case with autopsy. Arch Pathol 1949;48:435.
7. Sezary A, Levy-Coblentz G, Chauvillon P. Dermographisme et mastocytose. Bull Soc Fr Dermatol Syphiligr 1936;43: 359-61.
8. Sondergaard J, Asboe-Hansen G. Mastocytosis in childhood. In: Happle R, Grosshans E, editors. Pediatric dermatology. Berlin, Heidelberg: Springer-Verlag; 1987. p. 148-54.
9. Caplan RM. The natural course of urticaria pigmentosa. Arch Dermatol 1963;87:146-57.
10. Sagher F, Even-Paz. Mastocytosis and the mast cell. Chicago: Yearbook Medical Publishers, 1967.
11. Shaw JM. Genetic aspects of urticaria pigmentosa. Arch Dermatol 1968;97:137-8.
12. Selmanowitz VJ, Orentreich NO. A clinical genetic evaluation. J Heredity 1970;61:91-4.
13. Selmanowitz, VJ, Orentreich NO, Tiango CC. Uniovular twins discordant for cutaneous mastocytosis. Arch Dematol 1970;102:34-41.
14. Rockoff VS. Urticaria pigmentosa in identical twins. Arch Dermatol 1978;114:1227-8.
15. Lagunoff D, Chi EY. Cell biology of mast cells and basophils. In: Weissman G, editor. The biology of inflammation. Amsterdam: Elsevier/North Holland; 1980. p. 217-49.
16. Eady RAJ, Cowen T, Marshall TF, et al. Mast cell population density, blood vessel density and histamine content in normal human skin. Br J Dermatol 1979;100:623-33.
17. Weisner-Menzel L, Schulz B, Vakilzadeh F, et al. Electron microscopical evidence for a direct contact between nerve fibers and mast cells. Acta Derm Venereol 1981;61:465-9.
18. Rau K, Demitsu T, Puglielli, Tharp MD. Effect of human recombinant stem cell factor on human cutaneous mast cells [abstract]. J Invest Dermatol 1995;104:677.
19. Tharp MD, Glass MJ, Seelig LL Jr. Ultrastructural morphometric analysis of human mast cells from normal skin and pathologic cutaneous lesions. Am J Cutan Pathol 1988;15: 78-83.
20. Hashimoto K, Gross BG, Lever WF. An electron microscopic study of the degranulation of mast cell granules in urticaria pigmentosa. J Invest Dermatol 1966;46:139.
21. Orr TS. Fine structure of the mast cell with special reference to human cells. Scand J Respir Dis Suppl 1977;98:1-7.
22. Tharp MD. The mast cell and its mediators In: Goldsmith LA, editor. Physiology, biochemistry and molecular biology of the skin. New York: Oxford University Press, 1991. p. 1099-120.
23. Enerback L. Mucosal mast cells in the rat and in man. Int Arch Allergy Appl Immunol 1987;82:249-55.
24. Kramer H, Windrum GM. The metachromatic staining reaction. J Histochem Cytochem 1955;3:227-36.
25. Bergstresser PR, Tigelaar RE, Tharp MD. Conjugated avidin identifies rodent and human mast cells. J Invest Dermatol 1984;83:214-8.
26. Kasper CS, Tharp MD. Quantification of cutaneous mast cells using morphometric point counting and a conjugated avidin stain. J Am Acad Dermatol 1987;16:326-31.
27. Irani AA, Schechter NM, Craig SS, et al. Two types of human mast cells that have distinct neutral protease compositions. Proc Natl Acad Sci U S A 1986;83:4464-8.
28. Mikhail GR, Miller-Milinska A. Mast cell population in skin. J Invest Dermatol 1964;43:249-54.
29. Kirshenbaum AS, Kessler SW, Goff JP, et al. Demonstration of the origin of human mast cells from CD34+ bone marrow progenitor cells. J Immunol 1991;46:1410-5.
30. Kirshenbaum AS, Goff JP, Kessler SW, et al. Effect of IL-3 and stem cell factor on the appearance of human basophils and mast cells from CD34+ pluripotent progenitor cells. J Immunol 1992;148:772-7.
31. -cell population. Blood 1994;84:2489-96.
32. Lev S. Blechman JM, Givol D et al. Steel factor and c-kit protooncogene: genetic lessons in signal transduction. Crit Rev Oncog 1994;5:141-68.
33. Geissler EN, Ryan MA, Housman DE. The dominant-white spotting (W) locus of the mouse encodes the c-kit protooncogene. Cell 1988;55:185-92.
34. d genotype. In: Galli SJ, Austen KF, editors. Mast cell and basophil differentiation and function in health and disease. New York: Raven Press, 1989. p. 15-25.
35. Funasaka Y, Boulton T, Cobb M, et al. Y: c-kit kinase induces a cascade of protein tyrosine phosphorylation in normal human melanocytes in response to mast cell growth factor and stimulates mitogen-activated protein kinase but is down-regulated in melanomas. Mol Biol 1992;3:197-209.
36. Flanagan JG, Leder P. The c-kit ligand: a cell surface molecule altered in steel mutant fibroblasts. Cell 1991;63:185-94.
37. Nagata H, Worobec AS, Oh CK, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-KIT in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A 1995;92:10560-4.
38. Longley BJ, Tyrrell L, Lu S-Z et al. Somatic c-Kit activating mutation in urticaria pigmentosa and aggressive mastocytosis; establishment of clonality in a human mast cell neoplasm. Nature Genetics 1996;12:312-4.
39. Anderson DM, Lyman SD, Baird A, et al. Molecular cloning of mast cell growth factor, a hematopoietin that is active in both membrane bound and soluble forms. Cell 1990;63:235-43.
40. Longley BJ, Tyrrell L, Ma Y, et al. Chymase cleavage of stem cell factor yields a bioactive, soluble product. Proc Natl Acad Sci, U S A 1997;94:9017-21.
41. Vliagoftis H, Worobec AS, Metcalfe DD. Updates on cells and cytokines: the protooncogene c-kit and c-kit ligand in human disease. J Allergy Clin Immunol 1997;100:435-40.
42. Weidner N, Austen KJ. Evidence for morphologic diversity of human mast cells. An ultrastructural study of mast cells from multiple body sites. Lab Invest 1990;63:63-72.
43. Craig SS, Schwartz LB. Human MCTC type of mast cell granule: the uncommon occurrence of discrete scrolls associated with focal absence of chymase. Lab Invest 1, 1990;63:581-5.
44. Irani AA, Goldstein SM, Wintroub BU, et al. Human mast cell carboxypeptidase: selective localization of MCTC cells. J Immunol 1991;147:247-53.
45. Weidner N, Austen KF. Heterogeneity of mast cells at multiple body sites. Fluorescent determination of avidin binding and immunofluorescent determination of chymase, tryptase, and carboxypeptidase content. Pathol Res Pract 1993;189: 156-62.
46. Weidner N, Austen KF. Ultrastructural and immunohistochemical characterization of normal mast cells at multiple body sites. J Invest Dermatol 1991;96:26S-31S.
47. Bradding P, Okayama Y, Horvath PH, et al. Heterogeneity of human mast cells based on cytokine content. J Immunol 1995;155:297-307.
48. Longley BJ Jr., Tyrrell L, Shuzhuang L, et al. Chronically KIT-stimulated clonally-derived human mast cells show heterogeneity in different tissue microenvironments. J Invest Dermatol 1997;108:792-6
49. Miller L, Blank U, Metzger H, et al. Expression of highaffinity binding of human immunoglobulin E by transfected cells. Science 1989;244:334-7.
50. Blank U, Ra C, Miller L, et al. Complete structure and expression in transfected cells of high affinity IgE receptor. J Allergy Clin Immunol 1989;83:756-63.
51. Shimizu A, Tepler I, Benfey PN, et al. Human and rat mast cell high-affinity immunoglobin E receptors: characterization of putative alpha-chain gene products. Proc Natl Acad Sci U S A 1988;11:384-93.
52. Tepler I, Morton CC, Shimizu A, et al. The gene for the human mast cell high-affinity IgE receptor alpha chain: chromosomal localization to Iq21-q23 and RFLP analysis. Am J Hum Genet 1989;45:761-5.
53. Ra C, Jouvin MH, Blank U, et al. A macrophage Fc gamma receptor and the mast cell receptor for IgE share an identical subunit. Nature 1989;341:752-4.
54. Casale TB, Bowman S, Kaliner M. Induction of human cutaneous mast cell degranulation by opiates and endogenous peptides: Evidence for opiate and nonopiate receptor participation. J Allergy Clin Immunol 1984;73:775-81.
55. Coutts AA, Jorizzo JL, Eady RAJ, et al. Adenosine triphosphate evoked vascular changes in human skin: mechanisms of action. Eur J Pharmacol 1981;76:391-401.
56. Tharp MD, Welsch MP, Sullivan TJ. Cutaneous mast cell stimulation by adenosine-triphosphate (ATP). J Invest Dermatol 1982;78:355.
57. Lewis T. The blood vessels of the human skin and their responses. London: Shaw & Sons; 1927. p. 23-91.
58. Stead RH, Dixon MF, Bramwell NH. et al. Mast cells are closely opposed to nerves in the human gastrointestinal mucosa. Gastroenterology 1989;97:575-85.
59. Bienenstock J, Tomioko M, Stead R, et al. Mast cell involvement in various inflammatory processes. Am Rev Resp Dis 1987;135:5S-8S.
60. Galli SJ. New concepts about the mast cell. N Engl J Med 1993;328:257-65.
61. Uvnas B, Aborg C-H, Bergendorff A. Storage of histamine in mast cells: evidence for an ionic binding of histamine to protein carboxyls in the granule heparin-protein complex. Acta Physiol Scand 1970;78:1-25.
62. Bearen MA. Histamine. N Engl J Med 1976;294:30-6.
63. 2 receptors in the human peripheral circulation. Br J Pharmacol 1976;56:494-6.
64. 3-receptors. Nature 1987; 327:117-23.
65. Robertson I, Greaves MW. Responses of human skin blood vessels to synthetic histamine analogues. Br J Clin Pharmacol 1978;5:319-22.
66. Lemanske EF, Kaliner M. Late phase allergic reactions. Int J Dermatol 1983;22:401-9.
67. Kaliner M, Shelhamer JH, Ottesen EA. Effects of infused histamine: correlation of plasma histamine levels and symptoms. J Allergy Clin Immunol 1982;69:283-9.
68. Schayer RW. Catabolism of physiological quantities of histamine in vivo. Physiol Rev 1959;39:116-26.
69. Kapeller-Adler R. Histamine catabolism in vitro and in vivo. Fed Proc 1965;24:757-65.
70. Granerus G, Lonnqvist B, Roupe G. No relationship between histamine release measured as metabolite excretion in the urine, and serum levels of mast cell specific tryptase in mastocytosis. Agent Actions 1994;41:C127-C128.
71. Metcalf DD, Lewis RA, Silbert JE, et al. Isolation and characterization of heparin from human lung. J Clin Invest 1979;64:1537-43.
72. Stevens RL, Fox CC, Lichtenstein LM, et al. Identification of chondroitin sulfate E proteoglycans and heparin proteoglycans in the secretory granules of human lung mast cells. Proc Natl Acad Sci USA 1988;85:2284-7.
73. Schwartz LB, Garbarg AM, Pollard H. Tryptase from human mast cells: biochemistry, biology and clinical utility. In: Schwartz LB, editor. Neutral proteases of mast cells. Monographs in allergy. Basel: S Karger; 1990;27:90-113.
74. Schwartz LB. Regulation of tryptase from human lung mast cells by heparin: stabilization of the active tetramer. J Biol Chem 1986;261:7373-9.
75. Schechter NM, Irani AM, Sprows JL, et al. Identification of a cathepsin G-like proteinase in the MCTC type of human mast cell. Lab Invest 1990;63:581-5.
76. Schwartz LB, Irani AM, Roller K, et al. Quantitation of histamine, tryptase, and chymase in dispersed human T and TC mast cells. J Immunol 1987;138:2611-5.
77. Chan IJ, Tharp MD. Effects of rat mast cell protease I on cell metabolism. J Invest Dermatol 1994;103:84-7.
78. Goldstein SM, Kaempfer CE, Proud D, et al. Identification and partial characterization of human mast cell carboxypeptidase. J Immunol 1987;139:2724-9.
79. Goldstein SM, Kaempfer CE, Kealey JT, et al. Human mast cell carboxypeptidase: purification and characterization. J Clin Invest 1989;83:1630-6.
80. Goldstein SM, Leong J, Bunnett NW. Human mast cell proteases hydrolyze neurotensin, kinetensin and Leu5-enkephalin. Peptides 1991;12:995-1000.
81. Schwartz LB, Lewis RA,. Seldin D, et al. Acid hydrolases and tryptase from secretory granules of dispersed human lung mast cells. J Immunol 1981;126:1290-4.
82. Benyon RC, Robinson C, Church MK. Differential release of histamine and eicosanoids from human skin mast cells activated by IgE-dependent and non-immunological stimuli. Br J Pharmacol 1989;97:898-904.
83. Schleimer RP, MacGlashan DW, Peters SP, et al. Characterization of inflammatory mediator release from purified human lung mast cells. Am Rev Resp Dis 1986; 133:614-7.
84. Lewis RA. Prostaglandin D2 generation after activation of rat and human mast cells with anti-IgE. J Immunol 1982; 129:1627-31.
85. Flower RJ. Inflammatory effects of prostaglandin D2 in rat and human skin. Br J Pharmacol 1976;56:229-33.
86. Heavey DJ, Lumley P, Barrow SE, et al. Effects of intravenous infusions of D2 in patients with systemic mastocytosis. Prostaglandins 1984;28:755-67.
87. Roberts LJ, Sweetman BJ, Lewis RA, et al. Increased production of prostaglandin D2 in patients with systemic mastocytosis. N Engl J Med 1980;303:1400-4.
88. Goetzl EJ. Oxygenation products of arachidonic acid as mediators of hypersensitivity and inflammation. Med Clin North Am 1981;65:809-28.
89. 4) in human skin. J Invest Dermatol 1983:80:115-9.
90. Triggiani M, Hubbard WC, Chilton FH. Synthesis of 1acetyl-sn-glycero-3-phosphocholine by an enriched preparation of the human lung mast cell. J Immunol 1990;144: 4773-80.
91. Okayama Y, Petit-Frere C, Kassel O, et al. IgE-dependent expression of mRNA for IL-4 and IL-5 in human being mast cells. J Immunol 1995;155:1796-808.
92. Walsh LJ, Trinchieri G, Waldorf HA, et al. Human dermal mast cells contain and release tumor necrosis factor-α which induces endothelial leukocyte adhesion molecule-I. Proc Natl Acad Sci U S A 1991;88:4220-4.
93. Bradding P. Human mast cell cytokines. Clin Exp Allergy 1996;26:13-9.
94. Moller A, Lippert U, Lessman D, et al. Human mast cells produce IL-8. J Immunol 1993;154:3261-5.
95. Sugarman BJ, Aggarwal BB, Hass PE. Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro. Science 1995;230:943-5.
96. 2 production by human synovial cells and dermal fibroblasts. J Exp Med 1985;162:2163-8.
97. Ioffreda MD, Whitaker D, Murphy GF. Mast cell degranulation upregulates alpha-6 integrins on epidermal Langerhans cells. J Invest Dermatol 1993;101:150-4.
98. Klein LM, Lavker RM, Matis WL, et al. Degranulation of human mast cells induces an endothelial antigen central to leukocyte adhesion. J Proc Natl Acad Sci 1989;86:8972-6.
99. Schleimer RP, Sterbinsky SA, Kaiser J, et al. IL-4 induces adherence of human eosinophils and basophils but not neutrophils to endothelium: association with expression of VCAM-1. J Immunol 1992;148:1086-92.
100. Moser R, Fehr J, Olgiati L, et al. Migration of primed human eosinophils across cytokine-activated endothelial cell monolayers. Blood 1992;79:2937-45.
101. Webb T, Li C-Y, Yam L. Systemic mast cell disease: a clinical and hematopathologic study of 26 cases. Cancer 1982; 49:927-38.
102. Lennert K, Parwaresch M. Mast cells and mast cell neoplasia: a review. Histopathology 1979;3:349-65.
103. Travis W, Li C-Y, Bergstralh E, et al. Systemic Mast Cell Disease. Medicine 1988;67:345-68.
104. Ishizaka K, Ishizaka T. Identification of gamma-E antibodies as a carrier of reaginic activity. J Immunol 1967;99:1187-98.
105. Caufield JP, Lewis RA, Hein A, et al. Secretion in dissociated human pulmonary mast cells: evidence for solubilization for granule contents before discharge. J Cell Biol 1980;85: 299-311.
106. Dvorak AM, Schleimer RP, Lichtenstein LM, et al. Human mast cells synthesize new granules during recovery from degranulation: in vitro studies with mast cells purified from human lung. Blood 1988;71:76-85.
107. White MV, Kaplan AP, Haak-Frendscho M, et al. Neutrophils and mast cells: comparison of neutrophil-derived histaminereleasing activity with other histamine-releasing factors. J Immunol 1988;141:3575-83.
108. Alam R, Welter J, Forsythe PA, et al. Detection of histamine release inhibitory factor-and histamine releasing factor-like activities in bronchoalveolar lavage fluids. Am Rev Respir Dis 1990;141:666-71.
109. Subramanian N, Bray MA. Interleukin 1 releases histamine from human basophils and mast cells in vitro. J Immunol 1987;138:271-5.
110. Niimi N, Frances DM, Kermani F, et al. Dermal mast cell activation by autoantibodies against high affinity IgE receptor antibodies in chronic urticaria. J Invest Dermatol 1996; 106:1001-6.
111. Warner JA, MacGlashan DW, Lichtenstein LM. Heterogeneity of human Fc epsilon R1-bearing cells. Ciba Foundation Symp 1989;147:230-41.
112. Eady RAJ, Cowen T, Marshall TF, et al. Mast cell population density, k blood vessel density and histamine content in normal human skin. Br. J Dermatol 1979;100:623-33.
113. Sontheimer RD, Tharp MD. Immunological repertoire of the dermal microvascular unit. In: Nickoloff BJ, editor. Dermal immune system. Boca Raton: CRC Press, 1993. p. 117-49.
114. Hebda PA, Collins MA, Tharp MD. Mast cell and myofibroblast in wound healing. Dermatol Clin 1993;11:685-96.
115. Folkman J, Langer R, Linhadt R et al. Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone. Science 1983;221: 719-25.
116. Tharp MD. The interaction between mast cells and endothelial cells. J Invest Dermatol 1989;93:1073-125.
117. Marks RM, Rjoche WR, Czerniecki M, et al. Mast cell granules cause proliferation of human microvascular endothelial cells. Lab Invest 1986;55:289-94.
118. Lynch NR, Solomon JC. Passive local anaphylaxis: demonstration of antitumor activity and complementation of intratumor BCG. J Natl Cancer Inst 1977;58:1093-8.
119. Tharp MD, Kasper C, Thiele D, et al. Studies of connective tissue mast cell-mediated cytotoxicity. J Invest Dermatol 1989;93:423-8.
120. McDuffie FC, Sams WM Jr, Malonado JE, et al. Hypocomplementemia with cutaneous vasculitis and arthritis: possible immune complex syndrome. Mayo Clin Proc 1973; 78:340-8.
121. Natbony HS, Phillips MD, Elias JM, et al. Histologic studies of chronic idiopathic urticaria J Allergy Clin Immunol 1983; 71:177-83.
122. Callen JP, Hanno R. Pruritic urticarial papules and plaques of pregnancy (PUPPP): a clinicopathologic study. J Am Acad Dermatol 1981;5:401-5.
123. Solley GD, Gleich GJ, Jordon RE, et al. The late phase of the immediate wheal and flare reaction: its dependence on IgE antibodies. J Clin Invest 1976;58:408-20.
124. Zavadak D, Tharp MD. Chronic urticaria as a manifestation of the late phase reaction. Immunol Allergy Clin N Am 1995;15:745-59.
125. Sampson HA. Role of immediate food hypersensitivity in the pathogenesis of atopic dermatitis. J Allergy Clin Immunol 1983;71:437-80.
126. Hanafin JM. Atopic dermatitis. J Allergy Clin Immunol 1984;73:211-22.
127. Cooper KD, Kang K, Chan SC. Phosphodiesterase inhibition by Ro 20-1724 reduces hyper IgE synthesis by atopic dermatitis cells in vitro. J Invest Dermatol 1985;84:477-82.
128. Wintroub BU, Mihm MC Jr, Goetzl EJ, et al. Morphologic and functional evidence for release of mast cell products in bullous pemphigoid. N Engl J Med 1978;298:412-21.
129. Mark R, Greaves MW. Vascular reactions to histamine and compound 48/80 in human skin: suppression by a histamine H2 receptor-blocking agent. Br J Clin Pharmacol 1977;4: 367-71.
130. Teofoli P, Procacci P, Maresca M, et al. Itch and pain Int J Dermatol 1996;35:159-66.
131. Dowd P. Mechanisms of pruritus. In: Arndt KA, LeBoit PE, Robinson JK, Wintroub BU, editors. Cutaneous medicine and surgery. Philadelphia: WB Saunders Company, 1996. p. 154-9.
132. Kam PCA, Tan KH. Pruritus - itching for a cause or relief? Anaesthesia 1996;51:1133-8.
133. Greaves M. Pathophysiology and clinical aspects of pruritis. In: Fitzpatrick TB, Eisen AZ, Wolff K, Freedburg IM, Austen KF, editors. Dermatology in General Medicine. New York: McGraw-Hill Inc., 1993. p. 413-21.
134. Metcalfe D. Classification and diagnosis of mastocytosis: current status. J Invest Dermatol 1991;96:2S-4S.
135. Kettelhut BV, Metcalfe DD. Pediatric mastocytosis. J Invest Dermatol 1991;96:15S-18S.
136. Griffiths WAD, Daneshbod K. Pseudoxanthomatous mastocytosis. Br J Dermatol 1975;93:91-5.
137. Meneghini CL, Angelini G. Systemic mastocytosis with the diffuse crocodile-like pachydermic skin, pedunculated pseudofibromas and comedones. Br J Dermatol 1980;103:329-33.
138. Willemze R, Reiter DJ, Scheffer E, et al. Diffuse cutaneous mastocytosis with multiple cutaneous mastocytoma. Br J Dermatol 1980;102:601-7.
139. Soter NA. The skin in mastocytosis. J Invest Dermatol 1991; 96:32S-39S.
140. Orkin M, Good RA, Clawson CC, et al. Bullous mastocytosis. Arch Dermatol 1970:101:547-62.
141. Asinoff R, Soter NA, Freedburg I. Solitary mastocytoma in an adult. J Dermatol Surg Oncol 1993;19:487-8.
142. Tolmach JA. Urticaria pigmentosa-solitary lesion in an adult. Arch Dermatol 1962;86:545.
143. Kasper C, Freeman RG, Tharp MD. Diagnosis of mastocytosis subsets using a morphometric point counting technique. Arch Dermatol 1987;123:1017-21.
144. Horan RF, Austen KF. Systemic mastocytosis: retrospective review of a decade's clinical experience at the Brigham and Women's Hospital. J Invest Dermatol 1991;96:5S-14S.
145. Metcalfe DD. The treatment of mastocytosis: an overview. J Invest Dermatol 1991;96:55S-59S.
146. Sutter MC, Beaulieu G, Birt AR. Histamine liberation by codeine and polymyxin B in urticaria pigmentosa. Arch Dermatol 1962;86:217-21.
147. Fallon MD, Whyte MP, Teitelbaum SL. Systemic mastocytosis associated with generalized osteopenia. Human Pathol 1981;12:813-20.
148. Haney K, Russell W, Raila FA, et al. MRI characteristics of systemic mastocytosis of the lumbosacral spine. Skeletal Radiol 1996;25:171-3.
149. Ho LM, Lipper MH. Mastocytosis of the axial skeleton presenting as an epidural mass lesion. AJR 1996;167:716-8.
150. Avioli LV. Heparin-induced osteopenia: an appraisal. Adv Exp Med Biol 1975;52:375-91.
151. Raisz LG, Martin TJ. Prostaglandin in bone and mineral metabolism. In: Peck W, editor. Bone and mineral research. Amsterdam: Elsevier Science Publishers; 1983. p. 286-310.
152. Russell J, Russell S, Trupin K. The effect of histamine on the growth of cultured fibroblasts isolated from normal and keloid tissue. J Clin Physiol 1977;93:389.
153. Andrew SM, Freemont AJ. Skeletal mastocytosis. J Clin Pathol 1993;46:1033-5.
154. Linkhart TA, Linkhart SG, MacCharles DC, et al. Interleukin-6 messenger RNA expression and interleukin-6 protein secretion in cells isolated from normal human bone: regulation by interleukin-1. J Bone Min Res 1991;6:1285-94.
155. Parker RI. Hematologic aspects of mastocytosis: I. Bone marrow pathology in adult and pediatric systemic mast cell disease. J Invest Dermatol 1991;96:47S-51S.
156. McKenna MJ. Histomorphometric study of mast cells in normal bone, osteoporosis, and mastocytosis using a new stain. Calcif Tissue Int 1994;55:257-9.
157. Kettlehut BV, Parker RI, Travis WD, et al. Hematopathology of the bone marrow in pediatric cutaneous mastocytosis. J Clin Pathol 1989;91:558-62.
158. Avila NA, Ling A, Worobec AS, et al. Systemic mastocytosis: CT and US features of abdominal manifestations. Radiology 1997;202:367-72.
159. Mican J, Bisceglie A, Fong T, et al. Hepatic involvement in mastocytosis: clinicopathologic correlations in 41 cases. Hepatology 1995;22:1163-70.
160. Travis WD, Li Cy. Pathology of the lymph node and spleen in systemic mast cell disease. Mod Pathol 1986;1:4-14.
161. Metcalfe DD. The liver, spleen, and lymph nodes in mastocytosis. J Invest Dermatol 1991;96:45S-46S.
162. Yam LT, Chan CH, Li C-Y. Hepatic involvement in systemic mast cell disease. Am J Med 1986;80:819-26.
163. Scolapio JS, Wolfe J III, Malavet P, et al. Endoscopic findings in systemic mastocytosis. Gastrointestinal Endoscopy 1996;44:608-11.
164. Miner PB Jr. The role of the mast cell in clinical gastrointestinal disease with special reference to systemic mastocytosis. J Invest Dermatol 1991;96:40S-44S.
165. Baron T, Koehler R, Rodgers W, et al. Mast cell cholangiopathy: another cause of sclerosing cholangitis. Gastroenterology 1995;109:1677-81.
166. Rogers M, Bloomingdale K, Murawski B, et al. Mixed organic brain syndrome as a manisfestation of systemic mastocytosis. Psychosomatic Medicine 1986;48:437-47.
167. Soter NA, Austen F, Wasserman SI. Oral disodium cromoglycate in the treatment of systemic mastocytosis. N Engl J Med 1979;301:465-9.
168. Travis W, Li C-Y, Hoagland H, et al. Mast cell leukemia: report of a case and review of the literature. Mayo Clin Proc 1986;61:957-66.
169. Waters WJ, Lacson PS. Mast cell leukemia presenting as urticaria pigmentosa. Pediatrics 1957;19:1033-42.
170. Meggs WJ, Friedman MM, Kramer N, et al. Lymphadenopathic mastocytosis with eosinophilia [abstract]. 1985;33: 162A.
171. Craig SS, Schechter NM, Schwartz LB. Ultrastructural analysis of human T and TC mast cells identified by immunoelectron microscopy. Lab Invest 1988;58:682-91.
172. Lindell SE, Rorsman H, Westling H. Histamine formation in urticaria pigmentosa. Acta Derm Venereol 1961;41:277-80.
173. Poppel MH, Gruber WF, Silber R, et al. The roentgen manifestations of urticaria pigmentosa (mastocytosis). AJR Am J Roentgenol 1959;82:239-49.
174. Rosenbaum RC, Frieri K, Metcalfe DD. Patterns of skeletal scintigraphy and their relationship to plasma and urinary histamine levels in systemic mastocytosis. J Nucl Med 1984;25:859-64.
175. Lucaya J, Perez-Candela V, Celestina A et al. Mastocytosis with skeletal and gastrointestinal involvement in infancy. Two case reports and a review of the literature. Radiology 1979;131:363-6.
176. Feldman J. Histaminuria from histamine-rich foods. Arch Intern Med 1983;143:2099-102.
177. Granerus G. Urinary excretion of histamine, methyl histamine and methyl imidazoleactic acids in man under standardized dietary conditions. Scand J Clin Lab Invest (Suppl) 1968;104:59-68.
178. Granerus G, Roupe G. Increased urinary methyl imidiazole acetic acid (MeImAA) as an indicator of systemic mastocytosis. Agents Actions 1982;12:29-31.
179. Granerus G, Olafasson JH, Roupe G. Studies on histamine metabolism in mastocytosis. J Invest Dermatol 1983;80:410-6.
180. Keyzer JL, DeMonchy JGR, Van Doormaal JJ, et al. Improved diagnosis of mastocytosis by measurement of urinary histamine metabolites. N Engl J Med 1983;309:1603-5.
181. Van Gysel D, Oranje AP, Vermeiden I, et al. Value of urinary N-mernylhistamine measurements in childhood mastocytosis. J Am Acad Dermatol 1996;35:556-8.
182. Granerus G, Lonnqvist B, Roupe G. Histamine metabolism in mastocytosis patients treated with Interferon α-2b. Inflamm Res 1996;45:S41-S43.
183. Schwartz LB, Sakai K, Bradford TR, et al. The α form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis. J Clin Invest 1995;96:2702-10.
184. 2 J Invest Dermatol 1995;104:937-40.
185. Gandra DR, Mackenzie MR. Differential diagnosis of monoclonal gammopathy. Med Clin North Am 1988;72:1155-67.
186. Mitsui H, Furitss JT, Dvorak AM, et al. Development of human mast cells from umbilical cord blood cells in recombinant human and murine c-kit ligand. Proc Natl Acad Sci U S A 1993;90:735-9.
187. Yanigida M, Fukamachi H, Ohgami K, et al. Effects of T-helper 2 type cytokines, interleukin-3, IL-4, IL-5, and IL-6 on the survival of cultured human mast cells. Blood 1995; 8686:3705-14.
188. Longley BJ Jr., Morganroth GS, Tyrrell L, et al. Altered metabolism of mast cell growth factor (c-kit ligand) in cutaneous mastocytosis. N Engl J Med 1993;328:1302-7.
189. Hamann K, Haas N, Grabbe J, et al. Expression of stem cell factor in cutaneous mastocytosis. Br J of Dermatol 1995; 133:23-208.
190. Furitsu T, Tsujimura T, Tono T, et al. Identification of mutation in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J Clin Invest 1993;92:1736-44.
191. Longley BJ Jr., Tyrell L, Lu SZ, et al. Somatic c-kit activating mutation in urticaria pigmentosa and aggressive mastocytosis:establishment of clonality in a human mast cell neoplasm. Nat Genet 1996;12:312-4.
192. Nagata H, Okada T, Wojobec AS, et al. c-Kit mutation in a population of patients with mastocytosis. Int Arch Allergy Immunol 1997;113:184-6.
193. Tharp MD, Glass MJ, Seelig LL. Ultrastructural morphometric analysis of lesional skin mast cells from patients with systemic and nonsystemic mastocytosis. J Am Acad Dermatol 1988;18:298-306.
194. Swolin B, Rodjer S, Roupe G. Cytogenic studies and in vitro colony growth in patients with mastocytosis. Blood 1987;70: 1928-32.
195. Swolin B, Rodjer S, Al-Obaidy A, et al. A follow-up study of bone marrow chromosomes and in vitro colony growth in patients with mastocytosis. Acta Derm Venereol 1994;74: 163-7.
196. Lishner M, Confino-Cohen R, Mekori YA, et al. Trisomies 9 and 8 detected by fluorescence in situ hybridization in patients with systemic mastocytosis. J Allergy Clin Immunology 1996;98:199-204.
197. Swolin B, Weinfeld A, Westin J. A prospective long term cytogenetic study in polycythemia vera in relation to treatment and clinical course. Blood 1988;72:386-95.
198. Strife A, Clarkson B. Biology of chronic myelogenous leukemia: Is discordant maturation the primary defect? Semin Hematol 1988;25:1-19.
199. Fromer JL, Jaffee N. Urticaria pigmentosa and acute lymphoblastic leukemia. Arch Dermatol 1973;107:283-4.
200. Kors JW, Van Doormal JJ, Breukelman H, et al. Long-term follow-up of indolent mastocytosis in adults. J Intern Med 1996;239:157-64.
201. Scott HW, Parris WCV, Sandidge PC, et al. Hazards in operative management of patients with systemic mastocytosis. Ann Surg 1983;197:507-14.
202. Tharp MD, Chaker B, Glass MJ, et al. In vitro functional reactivities of cutaneous mast cells from patients with mastocytosis. J Invest Dermatol 1987;89:264-8.
203. 1-receptor antagonists: clinical pharmacology. Clin Exp Allergy 1990;10(Suppl 2):19-24.
204. Hirschowitz BI, Groake JF. Effect of cimetidine on gastric hypersecretion and diarrhea in systemic mastocytosis. Ann Intren Med 1979;90:769-71.
205. Frieri M, Alling DW, Metcalfe D. Comparison of the therapeutic efficacy of cromolyn sodium with that of combined chlorpheniramine and cimetidine in systemic mastocytosis. Am J Med 1985;78:9-14.
206. Friedman B, Santiago M, Berkebile C, et al. Comparison of azelastine and chlorpheniramine in the treatment of mastocytosis. J Allergy Clin Immunol 1993;92:520-6.
207. Richelson E. Tricyclic antidepressants and H1 receptors. Mayo Clin Proc 1979;54:669-74.
208. Turk J, Oates JA, Roberts LJ II. Intervention with epinephrine in hypotension associated with mastocytosis. J Allergy Clin Immunol 1983;71:189-92.
209. Roberts LJ, Fields JP, Oates JA. Mastocytosis with urticaria pigmentosa: a frequently unrecognized cause of recurrent syncope. Trans Assoc Am Physicians 1982;95:36-41.
210. Horan RF, Sheffer AL, Austen KF, et al. Cromolyn sodium in the management of systemic mastocytosis. J Allergy Clin Immunol 1990;25:852-5.
211. Zoelch EA, Alper JC, Bogaars H, et al. Treatment of bullous mastocytosis with disodium cromoglycate. J Am Acad Dermatol 1983;9:349-53.
212. Christophers E, Honigsmann H, Wolff K, et al. PUVA treatment of urticaria pigmentosa. Br J Dermatol 1978;98: 701-2.
213. Vella-Briffa D, Eady R, James M, et al. Photochemotherapy (PUVA) in the treatment of urticaria pigmentosa. Br J Dermatol 1983;109:67-75.
214. Kolde G, Frosch P, Czarnetzki B. Response of cutaneous mast cells to PUVA in patients with urticaria pigmentosa: histomorphometric, ultrastructural, and biochemical investigations. J Invest Dermatol 1984;83:175-8.
215. Granerus G, Roupe G, Swanbeck G. Decreased urinary histamine after successful PUVA treatment of urticaria pigmentosa. J Invest Dermatol 1981;76:1-3.
216. Stern RS, Land N. The carcinogenic risk treatments for psoriasis. Cancer 1994;73:2759-64.
217. Barton J, Lavker RM, Schechter NM, et al. Treatment of urticaria pigmentosa with corticosteroids. Arch Dermatol 1985;121:1516-23.
218. Kluin-Nelemans HC, Jansen JH, Breukelman H, et al. Response to interferon alpha-2b in a patient with systemic mastocytosis. N Engl J Med 1992;326:619-23.
219. Worobec A, Kirshenbaum A, Schwartz L, et al. Treatment of three patients with systemic mastocytosis with interferon alpha-2b. 1996;22:501-8.
220. Petit A, Pulik M, Gaulier A, et al. Systemic mastocytosis associated with chronic myelomonocytic leukemia: clinical features and response to interferon-alfa therapy. J Am Acad Dermatol 1995;32:850-3.
221. Einhorn S, Strander H. Interferon treatment of human malignancies-a short review. Med Oncol Tumor Pharmacother 1993;10:25-9.
222. Czarnetzki B, Algermissen B, Jeep S, et al. Interferon treatment of patients with chronic urticaria and mastocytosis. J Am Acad Dermatol 1994;30:500-1.
223. Harrison B, Ashford R, Hatton C. Systemic mastocytosis: a case with interferon-α and radiotherapy. Clin Lab Haemat 1994;16:291-4.
224. Johnstone PA, Mican JM, Metcalfe DD, et al. Radiotherapy of refractory bone pain due to neutral protease compositions. Proc Natl Acad Sci U S A 1986;83:4464-8.